Other · developed by Novo Nordisk
NNC9836-0001 is an agent given subcutaneously, studied in type 2 diabetes mellitus.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07896109 | Phase 1 | Diabetes Mellitus, Type 2 | Recruiting | NVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diabetes Mellitus, Type 2
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVO page.
See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVO catalysts and pipeline →